VERACYTE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.48 USD | +1.46% |
|
+5.83% | -25.72% |
| Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
| Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 3.32 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is highly valued given the cash flows generated by its activity.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -25.72% | 1.54B | C+ | ||
| -15.90% | 11.13B | A- | ||
| +65.19% | 3.6B | D+ | ||
| -29.91% | 2.26B | C | ||
| -14.31% | 2.16B | - | B- | |
| +37.10% | 1.17B | B- | ||
| -2.40% | 744M | C+ | ||
| -38.88% | 432M | C- | ||
| +13.72% | 357M | - | - | |
| +15.53% | 225M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VCYT Stock
- Ratings Veracyte, Inc.
